Loading news...
Topicus is part of a Constellation Software spin-out. However, they still roll up European VMS firms across public and private niches. These subsidiaries remain autonomous business units, and TOITF's M&A portfolio blends TSS (over 180 companies) with the Topicus platform cluster. This is how TOITF can serve SaaS targeting education, healthcare, government, finance, legal, and other regulated verticals.
DALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates (“USNA” or the “Company”), a physician services organization dedicated to transforming community-based neurology care. Through this partnership, USNA will serve neurology practices and their patients across a broad spectrum of neurological indications. Nitin Jain will serve as USNA's Chief Executive Officer and Brad Hively will serve as Chairman and co-founder. Prior to this role, Nitin Jain served as President of Value Based Care for U.S. Renal Care, and Brad Hively served as CEO of The Oncology Institute (NASDAQ: TOI).
Rakesh Panda appointed Chief Information Officer Nolan Mariano appointed Chief People Officer CERRITOS, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) announced today the promotions of Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer.
The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point.
CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise.
The Oncology Institute has struck deals to care for cancer patients in five states, which leaves room for growth. It's currently treating nearly 2 million patients.
NewGenIvf Group (NASDAQ: NIVF - Get Free Report) and Oncology Institute (NASDAQ: TOI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations. Institutional and Insider Ownership 66.2% of NewGenIvf
The Oncology Institute, Inc. ( TOI ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO & Executive Director Rob Carter - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Presentation Operator Greetings, and welcome to The Oncology Institute Third Quarter 2025 Earnings Call.
The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.18 per share a year ago.
Partnership deployed touchless prior authorization system in eight weeks, achieving 95% reduction in authorization workload Partnership deployed touchless prior authorization system in eight weeks, achieving 95% reduction in authorization workload
CERRITOS, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that the company will release its third quarter 2025 financial results after the market close on Thursday, November 13, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its third quarter results on November 4, 2025.
Big-cap stocks like Nvidia and Palantir steal attention. But now investors are scoring gains on small caps not in the S&P 500.
Topicus.com Inc. (TOI:CA) is a leading European vertical market software acquirer, benefiting from a fragmented European market and low Private Equity competition. TOI's record acquisition spending in 2025, strong organic growth, and successful AI integration position it for accelerated earnings and organic growth. Recent investments in Asseco Poland and Cipal Schaubroeck NV expand TOI's geographic reach and deepen its expertise in public sector and enterprise software.
The Oncology Institute (TOI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CERRITOS, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, today announced the launch of its Lung Cancer Center of Excellence in Fort Lauderdale, Florida. The new center will be led by world-renowned thoracic oncologist Dr. Edgardo S. Santos Castillero, whose career has been defined by groundbreaking research, clinical excellence, and a deep commitment to patient care.
The Oncology Institute has achieved a strong growth in revenue in the previous years, justifying its stock price movement. We believe TOI will still be able to grow in the coming quarters while currently trading at a discount. Risks remain high, warranting careful positioning.
The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Daniel Virnich - CEO & Executive Director Mark Hueppelsheuser - Corporate Participant General Counsel - Corporate Participant Robert Carter - Chief Financial Officer Conference Call Participants David Michael Larsen - BTIG, LLC, Research Division Robert Michael LeBoyer - NOBLE Capital Markets, Inc., Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Operator Ladies and gentlemen, greetings, and welcome to the Oncology Institute Second Quarter 2025 Earnings Call.
CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended June 30, 2025.
Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New Chairman